@article{TCR12822,
author = {Victor C. Kok},
title = {Genomic mutational profiles of metastatic breast cancer: obtaining them early and during the continuum of oncological care},
journal = {Translational Cancer Research},
volume = {6},
number = {Suppl 2},
year = {2017},
keywords = {},
abstract = {The era of incorporating tumor genomic profiling in metastatic breast cancer (MBC) management using histopathology, immunohistochemistry, and fluorescence in situ hybridization information for tailoring cancer treatment is on the horizon. Commercialized tumor profiling using next-generation sequencing (NGS) with massive parallel sequencing and high-throughput technology is now available at an affordable price. A caveat is that NGS diagnostics should be performed in a Clinical Laboratory Improvement Amendments-certified and College of American Pathologists-accredited academic or commercial laboratory. Outside clinical trial settings, an increasing number of clinical oncologists feel comfortable accepting this technology, and some have already considered it as an essential companion diagnostic test in determining potentially actionable targets for oncological therapeutics. Deep sequencing is required to identify mutations within the tumor proper because normal cell contamination can occur and tumors themselves likely contain multiple subclones of cancer cells (1).},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/12822}
}